Английская Википедия:Brian Druker

Содержание

Текст

Текст

Текст

Текст

Текст

Текст

Текст

Текст

Текст

Шаблон:Short description Шаблон:Infobox scientist Brian J. Druker (born April 30, 1955) is a physician-scientist at Oregon Health & Science University (OHSU), in Portland, Oregon. He is the director of OHSU's Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, Associate Dean for Oncology in the OHSU School of Medicine, and professor of medicine.

Druker helped develop imatinib (Gleevec), the first medication that specifically targets cancer cells, for the treatment of chronic myeloid leukemia (CML). In 2001, Gleevec gained FDA approval in record time and landed on the cover of Time magazine. Druker’s work launched the era of precision cancer medicine, setting the stage for future discoveries in the quest to end cancer.

He is the recipient of the 2009 Lasker-DeBakey Clinical Medical Research Award, the 2012 Japan Prize in Healthcare and Medical Technology, the 2013 Albany Medical Center Prize in Medicine and Biomedical Research, and the 2019 Sjöberg Prize, among others. He has been called "Oregon's best-known scientist".

Education

Druker earned both his B.A. degree in chemistry and M.D. degree from the University of California, San Diego. He completed his internship and residency in internal medicine at Barnes Hospital, Washington University School of Medicine in St. Louis from 1981 to 1984.

Teaching and Research

Шаблон:Expand section Druker was a fellow in medical oncology at Dana–Farber Cancer Institute at Harvard Medical School from 1984 to 1987. He began working at Oregon Health & Science University (OHSU) in 1993.

In May 2007, he became director of the OHSU Cancer Institute—renamed the Knight Cancer Institute in October 2008 following a $100 million donation from Nike co-founder Phil Knight.

Druker's research is focused on translating the knowledge of the molecular pathogenesis of cancer into specific therapies and investigating the optimal use of these molecularly targeted agents. He performed preclinical studies that led to the development of imatinib (Gleevec) for chronic myeloid leukemia (CML) and then spearheaded the highly successful clinical trials of imatinib, which led to FDA approval of the drug in record time. This work changed the life expectancy of patients with CML from an average of 3 to 5 years to a 89% five-year survival, and has resulted in a paradigm-shift in cancer treatment from non-specific chemotherapy to highly targeted therapeutic agents. Druker has been widely recognized for his work in developing Gleevec, but has been publicly critical of the drug's high price for patients.

In 2015, Druker celebrated the completion of the Knight Cancer Challenge, raising $1 billion for research at the Knight Cancer Institute. The Oregon Legislature and more than 10,000 donors from Oregon and beyond matched a $500 million grant from Phil and Penny Knight. The challenge gave the institute the funding to launch the Cancer Early Detection Advanced Research Center.

Druker also helped lead a national clinical trial to find effective treatments for acute myeloid leukemia (AML). The Beat AML clinical trial, sponsored by the Leukemia & Lymphoma Society (LLS), is a joint effort by medical centers, drug makers and the Food and Drug Administration.

Memberships and awards

Druker was an investigator of Howard Hughes Medical Institute (HHMI) from 2002 to 2019. He was elected to the National Academy of Medicine (formerly Institute of Medicine) in 2003 and the National Academy of Sciences in 2007. He is a member of the American Society for Clinical Investigation, Association of American Physicians, American Academy of Arts and Sciences, American Association for the Advancement of Science, American Society of Hematology, American Society for Microbiology, American Society of Clinical Oncology, American Association for Cancer Research, Children’s Oncology Group, and The American Society for Cell Biology. Druker has received the following awards, among others:

• Translational Research Award, Burroughs Wellcome Fund (2000)
• Charles Rodolphe Brupbacher Prize for Cancer Research, Charles Rodolphe Brupbacher Stiftung (2001)
• AACR-Richard and Hinda Rosenthal Foundation Award (2001)
• Warren Alpert Foundation Prize, Harvard Medical School (2001)
• Dameshek Prize, The American Society of Hematology (2001)
• Medal of Honor, American Cancer Society (2002)
• Robert-Koch Prize, Robert Koch Foundation, Cologne, Germany (2005)
• Golden Plate Award, Academy of Achievement (2007)
• Keio Medical Science Prize, Keio University Medical Science Fund, Tokyo, Japan (2007)
• European Inventor of the Year, Industry, European Patent Office (2009)
• The Rowley Prize, International CML Foundation (2009)
• Lasker-DeBakey Clinical Medical Research Award, Albert and Mary Lasker Foundation (2009)
• Meyenburg Award for Cancer Research, Meyenburg Foundation, Heidelberg, Germany (2009)
• Stanley J. Korsmeyer Award, American Society for Clinical Investigation (2011)
• Ernest Beutler Lecture and Prize, American Society of Hematology (2011)
• The Japan Prize in Healthcare and Medical Technology, The Japan Prize Foundation (2012)
• Dickson Prize in Medicine, University of Pittsburgh School of Medicine (2012)
• UCSF Medal, University of California San Francisco (2013).
• Giants of Cancer Care, OncLive (2013)
• A. Alfred Taubman Prize for Excellence in Translational Medical Science (2013)
• The Albany Medical Center Prize in Medicine and Biomedical Research (2013)
• Honorary Doctorate, Erasmus University Rotterdam (2013)
• Hamdan Award for Medical Research Excellence, Sheikh Hamdan Bin Rashid Al Maktoum Awards for Medical Sciences (2014).
• Tang Prize in Biopharmaceutical Science, The Tang Prize Foundation (2018)
• Prince Mahidol Award in the Field of Medicine, Prince Mahidol Award Foundation (2019)
• Sjöberg Prize, The Royal Swedish Academy of Sciences (2019)
• Rell Sunn Award, Moores Cancer Center at UC San Diego Health (2019)
• August M. Watanabe Prize in Translational Research, Indiana Clinical and Translational Sciences Institute (2020)
• Lifetime Achievement Award, Stanford Drug Discovery Symposium (2023)

Personal

Druker is married to Alexandra Hardy, a one-time reporter for People magazine, and the couple have three children (as of 2009). An earlier marriage, to Barbara Rodriguez in 1990, ended in divorce in 1999.

External links

• Brian Druker Seminars: "Imatinib as a Paradigm of Targeted Cancer Therapies"